Advances in pancreatic cancer care

Abstract

Pancreatic cancer remains one of the deadliest cancers, mainly due to late diagnosis. Current screening methods and biomarkers lack sufficient sensitivity and specificity, resulting in most patients being diagnosed at an advanced stage. Surgical removal of the tumor combined with chemotherapy is essential for cure but carries a high risk of complications. Neoadjuvant chemotherapy is increasingly used to improve survival. Quality of life and patient involvement in treatment decisions are important because of the limited effectiveness and significant side effects of treatments.

Biomarkers like CA 19-9 have limited diagnostic value, but combining them with others and analyzing N-glycosylation profiles shows promise for early detection, especially in high-risk individuals. Pancreatic cancer also has a high risk of venous thromboembolism (VTE), which worsens prognosis. Treatment with low molecular weight heparin (LMWH) reduces this risk but can increase bleeding.

Shared decision-making between patients and doctors is essential but can be improved through structured tools and training. Future research focuses on personalized treatment guided by biomarkers and optimizing thrombosis prevention. Multidisciplinary care and AI support may enhance patient-centered care and treatment outcomes.